Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension

F Ichida; K Uese; S Tsubata; I Hashimoto; Y Hamamichi; K Fukahara; A Murakami; T Miyawaki

doi:10.1016/s0002-9149(97)00447-5

Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension

Am J Cardiol. 1997 Sep 1;80(5):662-4. doi: 10.1016/s0002-9149(97)00447-5.

Authors

F Ichida¹, K Uese, S Tsubata, I Hashimoto, Y Hamamichi, K Fukahara, A Murakami, T Miyawaki

Affiliation

¹ Department of Pediatrics, Toyama Medical and Pharmaceutical University, Japan.

PMID: 9295007
DOI: 10.1016/s0002-9149(97)00447-5

Abstract

Combined administration of inhaled nitric oxide and beraprost sodium resulted in a more intense decrease in pulmonary vascular resistance than nitric oxide given alone (mean -33% vs -45%, p <0.05), without serious systemic hypotension. Combined therapy with nitric oxide and beraprost sodium is highly desirable in treating primary and secondary pulmonary hypertension in children.

MeSH terms

Child
Child, Preschool
Cyclic AMP / blood
Cyclic GMP / blood
Drug Synergism
Epoprostenol / analogs & derivatives*
Epoprostenol / pharmacology
Humans
Hypertension, Pulmonary / drug therapy*
Infant
Lung / drug effects
Lung / physiology*
Nitric Oxide / pharmacology*
Vascular Resistance
Vasodilation / drug effects*
Vasodilator Agents / pharmacology*

Substances

Vasodilator Agents
Nitric Oxide
beraprost
Epoprostenol
Cyclic AMP
Cyclic GMP